TV-46763

Drug Teva Pharmaceuticals USA, Inc.
Total Payments
$2.6M
Transactions
27
Doctors
0
Companies
1

Payment Trends by Year

Year Amount Transactions Doctors
2017 $2.6M 27 0

Payments by Nature

Nature of Payment Amount Transactions Share
Unspecified $2.6M 27 100.0%

Research Studies & Clinical Trials

Study Name Sponsor Amount Doctors
TV46763-AP-10027 Teva Pharmaceuticals USA, Inc. $2.0M 0
A Study to Investigate the Food Effect and to Evaluate the Relative Bioavailability of Three Test Formulations of TV-46763 (Hydrocodone Bitartrate and Acetaminophen Tablets, 10 mg/325 mg) CII (CIMA Labs Inc.) in Healthy Adult Subjects Teva Pharmaceuticals USA, Inc. $241,568 0
TV46763-FE-10090 Teva Pharmaceuticals USA, Inc. $202,481 0
TV46763-BA-10063 Teva Pharmaceuticals USA, Inc. $173,867 0
TV46763-AP-10062 Teva Pharmaceuticals USA, Inc. $25,525 0
TV46763-PK-10130 Teva Pharmaceuticals USA, Inc. $15,634 0
TV46763-BE-10079 Teva Pharmaceuticals USA, Inc. $49.03 0

Top Doctors Receiving Payments for TV-46763

Doctor Specialty Location Total Records
Unknown Salt Lake City, UT $2.6M 27

About TV-46763

TV-46763 is a drug associated with $2.6M in payments to 0 healthcare providers, recorded across 27 transactions in the CMS Open Payments database. The primary manufacturer is Teva Pharmaceuticals USA, Inc..

Payment data is available from 2017 to 2017. In 2017, $2.6M was paid across 27 transactions to 0 doctors.

The most common payment nature for TV-46763 is "Unspecified" ($2.6M, 100.0% of total).

TV-46763 is associated with 7 research studies, including "TV46763-AP-10027" ($2.0M).